E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
progesterone as luteal phase supplementation in frozen embryo transfer cycles |
|
E.1.1.1 | Medical condition in easily understood language |
frozen embryo transfer cycles for infertility treatment |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Reproductive physiologi cal processes [G08] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of the study is to investigate the efficacy of dydrogesterone 30 mg compared to MVP 800 mg daily for LPS in HRT FET cycles, as confirmed by visualization of fetal heart activity by pelvic ultrasound assessment of ongoing pregnancy at 12 weeks of gestation. |
|
E.2.2 | Secondary objectives of the trial |
• To investigate positive serum hCG rate, clinical pregnancy rate (defined as the presence of ≥1 gestational sac following transvaginal ultrasound), miscarriage rate before 12 weeks of gestation and between 12 to 22 weeks of gestation. • To investigate the live birth rate, pregnancy complications, time of delivery (gestational week), and newborn health and safety parameters, including congenital malformations. • To investigate the safety and tolerability of dydrogesterone 30 mg daily versus MVP 800 mg daily for LPS in FET cycles in ART. • To investigate patient reported outcomes such as convenience and global satisfaction of using dydrogesterone 30 mg versus MVP 800 mg daily for LPS in FET cycles in ART. • To systematically investigate the rate of preterm birth (<Week 37) and pre-eclampsia
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• ≤40 years of age at the time of IVF/ICSI treatment • BMI ≥18 to ≤30 kg/m2 with a documented history of infertility • Have undergone COS as part of an ART treatment and have had an unsuccessful fresh embryo transfer in that cycle, OR, have undergone freeze all strategy • Scheduled to undergo FET with a standard exogenous/programmed hormonal replacement therapy (HRT) regimen • Have at least 1 blastocyst vitrified on the 5th or 6th day after oocyte retrieval • Elective single embryo (blastocyst) transfer (SET) • Normal ultrasound examination at enrollment (or if <12 months old) • Signed patient authorization for use/disclosure of data.
|
|
E.4 | Principal exclusion criteria |
• Women with a history of recurrent miscarriage, defined as >2 consecutive miscarriages (biochemical pregnancy losses are not included) • Absence of implantation (serum hCG = negative) after two consecutive cycles of IVF, ICSI or FET where the cumulative number of transferred embryos was >4 cleavage-stage embryos and >2 blastocysts • Presence of hydrosalpinx that is not surgically treated • Endometrial abnormalities on scanning during ovarian stimulation, such as endometrial polyp(s), sub mucosal fibroid(s), endometrial hyperplasia, endometrial fluid accumulation, or endometrial adhesions • Participating in another clinical study at the same time • Known allergic reactions to dydrogesterone or other progestogens products • Any contraindication or other condition that precludes use of dydrogesterone in a particular patient, in accordance with the precautions listed in the locally approved label • Mental disability or any other lack of fitness, in the Investigator's opinion, to preclude subjects in or to complete the study • History of prior chemotherapy • Contraindication for pregnancy • Transfer of >1 embryo
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
For the purposes of the primary endpoint, ongoing pregnancy will be confirmed by visualization of fetal heart activity via pelvic (vaginal/abdominal) ultrasound examination at 12 weeks of gestation. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
- Live birth rate and time of delivery - Tolerability and safety - Patient reported outcomes - Newborn wellbeing and safety - Biochemical pregnancy - Clinical pregnancy rate - Miscarriage rate - Rate of preterm birth (<Week 37) and pre-eclampsia - Occurrence of antenatal bleeding, ultrasonographic abnormalities, gestational diabetes, cholestasis - Implantation rate - Blastocyst development score - Number of cryopreserved embryos - Summary characteristics of COS cycle - HRT cycle outcomes
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Day 5-6 of LPS (Day of FET)
Day 14-18 of LPS (Pregnancy test)
Day 33-39 of LPS (Verification of pregnancy)
Day 68-74 of LPS (Ongoing pregnancy)
Week 21-22 of pregnancy
4-6 weeks post delivery |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |